Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company's lead product candidate, XMT-1536, is an ADC targeting NaPi2b, a clinically validated ADC target expressed in multiple solid tumors, including ovarian and lung cancers. Mersana Therapeutics is headquartered in Cambridge, Massachusetts.